Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3251)	9/27/2002 2:35:04 PM
From: scaram(o)uche	of 4974

Triangle: Once-Daily Coviracil Regimen Superior To Zerit Friday September 27, 10:32 am ET SAN DIEGO -(Dow Jones)- Triangle Pharmaceuticals Inc. (NasdaqNM:VIRS - News) said results from a Phase III trial show its Coviracil HIV treatment is safer and more effective than Bristol-Myers Squibb Co.'s Zerit. In a press release Friday, Triangle said the 48-week, double-blind trial compared once-a-day Coviracil to Zerit given twice a day, each combined with a complementary regimen of Bristol-Myers' Sustiva and Videx EC given once a day. The trial, dubbed FTC-301, enrolled 571 patients, 85% of them male, in the U.S., Europe, Mexico and South America. "This trial illustrated the potential of successfully treating patients with fully once-a-day regimens," said Franck Rousseau, executive vice president of research, development and medical in Friday's statement. Triangle submitted a new drug application for Coviracil to the Food and Drug Administration earlier this month.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next